Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905527 · ClinicalTrials.gov registry record
Adherence Trial With MS LifeLines ® Services
A clinical trial, sponsored by EMD Serono.
- Terminated
- Registry status
- 306
- Enrollment target
NCT01905527: Clinical Trial study, sponsored by EMD Serono.
NCT01905527 is a clinical trial that was terminated before completion, run by EMD Serono. The registered enrollment target is 306 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01905527 was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- 306 participants
- Enrollment target
Study Summary
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication adherence and treatment persistence with Rebif ® subcutaneous three times a week.
Interventions
- OTHER Group B
- OTHER Standard Services of Group A (Group A1)
- OTHER Customized Services of Group A (Group A2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-01 |
Why NCT01905527 stopped before completion
NCT01905527 is an observational study that tracks outcomes without assigning an intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Group B is the first listed.
NCT01905527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01905527 about?
NCT01905527 is a clinical study titled "Adherence Trial With MS LifeLines ® Services". This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication adherence and treatment persistence with Rebif ® subcutaneous three times a ...
What is the current status of trial NCT01905527?
This trial is currently terminated. The enrollment target is 306 participants. The study started on 2013-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01905527?
The interventions under investigation include: Group B (OTHER), Standard Services of Group A (Group A1) (OTHER), Customized Services of Group A (Group A2) (OTHER).
Who is sponsoring clinical trial NCT01905527?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia